Medical specialties

Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy

Retrieved on: 
Wednesday, August 4, 2021

The manuscript, titled Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy, was published online.

Key Points: 
  • The manuscript, titled Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy, was published online.
  • Patients who completed the PALISADE trial were eligible to enter the ARC004 open-label follow-on study, which evaluated the long-term efficacy and safety of daily PALFORZIA dosing beyond one year (52 weeks).
  • After two years of daily PALFORZIA treatment, 80.8% of study participants tolerated 2000 mg of peanut protein in the double-blind, placebo-controlled food challenge.
  • PALISADE (Peanut Allergy oral Immunotherapy Study of AR101 for Desensitization) was an international, randomized (3:1), double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of AR101 in patients with peanut allergy.

Viz.ai Receives New Technology Add-on Payment Renewal for Stroke AI Software from CMS

Retrieved on: 
Wednesday, August 4, 2021

The reimbursement opportunity will continue to give more patients access to life-changing stroke technology, which has demonstrated significant improvements to patient outcomes through FY 2022.

Key Points: 
  • The reimbursement opportunity will continue to give more patients access to life-changing stroke technology, which has demonstrated significant improvements to patient outcomes through FY 2022.
  • While other AI technology companies were evaluated, only Viz LVO was renewed for reimbursement through the demonstration of strong clinical outcomes.
  • CMS first granted Viz LVO NTAP in September 2020 by issuing a groundbreaking ruling which uniquely granted Viz LVO the first ever NTAP for artificial intelligence software.
  • Viz LVO is also the first FDA-cleared AI technology indicated to automatically detect and triage suspected large-vessel occlusions.

Lenzilumab Treatment May Provide Enhanced Likelihood of Survival Without Ventilation in Hospitalized Black and African-American COVID-19 Patients

Retrieved on: 
Wednesday, August 4, 2021

In the overall population with CRP

Key Points: 
  • In the overall population with CRP
  • LIVE-AIR Phase 3 study met its primary endpoint of survival without ventilation demonstrating a 1.54-fold improvement overall and trended to a 2.68-fold improvement in Black and African-American patients.
  • This study was a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial for the treatment and prevention of serious and potentially fatal outcomes in patients hospitalized with COVID-19 pneumonia.
  • The primary endpoint was the difference between lenzilumab treatment and placebo treatment in SWOV through day 28 following treatment.

RightEye Launches Eye Care’s First Automated Sensorimotor Exam for Binocular Vision Testing

Retrieved on: 
Wednesday, August 4, 2021

RightEye LLC, an advanced eye-tracking technology company, has launched the worlds first automated, quantitative sensorimotor exam system.

Key Points: 
  • RightEye LLC, an advanced eye-tracking technology company, has launched the worlds first automated, quantitative sensorimotor exam system.
  • The importance of this test is emphasized by the American Medical Association which lists a quantitative sensorimotor exam as a required element of a comprehensive eye exam.
  • "RightEye Sensorimotor was designed to integrate seamlessly into an eye care providers pre-test and exam lanes, said Keith Smithson, OD, Northern Virginia Doctors of Optometry.
  • By running RightEye Sensorimotor on every patient, eye care doctors are able to elevate their care and identify previously unaddressed binocular vision and oculomotor dysfunction."

Aditxt Provides Update on AditxtReprogramming’s™ Apoptotic DNA Immunotherapy Therapeutic Platform

Retrieved on: 
Wednesday, August 4, 2021

Meanwhile, Aditxt has continued to strengthen the data set that will be supporting regulatory submissions for the Apoptotic DNA Immunotherapy (ADi) platform for evaluation of ADi in clinical studies for skin allografting and type 1 diabetes in addition to the trials planned for psoriasis.

Key Points: 
  • Meanwhile, Aditxt has continued to strengthen the data set that will be supporting regulatory submissions for the Apoptotic DNA Immunotherapy (ADi) platform for evaluation of ADi in clinical studies for skin allografting and type 1 diabetes in addition to the trials planned for psoriasis.
  • Broadening the therapeutic programs to include MS is intended to address an important clinical need in addition to demonstrating the utility of ADi as an antigen-specific immune tolerance platform.
  • Aditxt is continuing to build its patent portfolio protecting ADi with the addition of new patent families in 2021.
  • Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming.

Gennao Bio to Participate in 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021

Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that management will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021.

Key Points: 
  • Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced that management will participate in the 2021 Wedbush PacGrow Healthcare Conference, being held virtually from August 10-11, 2021.
  • The details are as follows:
    Members of the Gennao Bio management team will also host investor meetings during the conference.
  • Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.
  • Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.
  • The session entitled HAE There- Development Landscape in Hereditary Angioedema (HAE) will include an overview of the HAE treatment landscape, information about Catabasiss lead program QLS-215, and a Q&A session.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast

Retrieved on: 
Wednesday, August 4, 2021

ET to review its second quarter 2021 financial results and provide an update on the company.

Key Points: 
  • ET to review its second quarter 2021 financial results and provide an update on the company.
  • Gamida Cell will also provide an update on its pipeline of NAM-enabled natural killer (NK) cell therapies, including GDA-201 and genetically-modified NK cell constructs.
  • The webcast will be available on the Investors & Media section of the Gamida Cell website at www.gamida-cell.com .
  • Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases.

WTUS21 Virtual Announces Speakers for 2nd Annual Event, August 19th

Retrieved on: 
Wednesday, August 4, 2021

SCOTTSDALE, Ariz., Aug. 4, 2021 /PRNewswire-PRWeb/ -- WeedTechUS, a FinTech event for Cannabis, CBD and Hemp payments, is pleased to announce its lineup of speakers for WTUS21, the 2nd annual conference for cannabis payments, POS technology, and compliance guidelines takes place August 19th, 2021.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 4, 2021 /PRNewswire-PRWeb/ -- WeedTechUS, a FinTech event for Cannabis, CBD and Hemp payments, is pleased to announce its lineup of speakers for WTUS21, the 2nd annual conference for cannabis payments, POS technology, and compliance guidelines takes place August 19th, 2021.
  • Marla Ellerman, Executive Director, WeedTechUS, said, "This has been a pivotal year for the cannabis, CBD and hemp industries.
  • We look forward to hear industry leaders address a range of issues and our near-term future roadmap."
  • Attendee admission is covered in full by WTUS21 sponsors, so that businesses can hear from innovators and thought leaders about cannabis, hemp and CBD compliance that is always shifting in our industry.

Biotech Founder, Monzer Hourani, Calls for Urgent Action in Open Letter to President Biden: "We cannot be afraid to 'follow the science,' a solution of many requires bold decisions."

Retrieved on: 
Wednesday, August 4, 2021

The IVP science is based on a patent-pending design to disinfect the air using heat--"catching and killing" actual SARS-CoV-2 and other submicron airborne pathogens, including anthrax spores, instantaneously, without impacting the ambient air temperature. The Biodefense Air Protection System is installed into air conditioners and mobile units providing anti-viral and cleaning power to all indoor pollutants, molds, pollen etc. The filters provide a scientific advantage to any HVAC filter on the market, including HEPA, which is not effective in killing any airborne pathogens. In turn, IVP helps the energy efficiency and sustainability of our buildings, schools, and healthcare facilities. 

Key Points: 
  • Do we really know what it is to be immune from COVID-19, and for how long will we be protected by the bioscience of a vaccine?
  • We cannot be afraid to 'follow the science' a solution of many requires bold decisions," Hourani stated, in his cry for help from President Biden and his administration.
  • Houston-based Integrated Viral Protection, LLC (IVP) is a biotech company formed to promote anti-COVID-19 technology based on engineering and science.
  • The technology has received certifications for safety and effectiveness, as well as meeting FDA guidelines for sale during the COVID-19 pandemic.